1. Introduction {#sec1}
===============

Breast cancer is the major form of female cancer that is responsible for 548,000 deaths or 7% of all cancer deaths in women \[[@B1], [@B2]\]. In Malaysia, breast cancer is the most common form of cancer in all age groups of women \[[@B3]\] and Infiltrating ductal carcinoma (IDC) is the most common form of breast cancer that made up \~85% of all breast cancer cases \[[@B4]\]. Over these years, progress has been made on the study of molecular pathways, including the roles of hormones and receptors in cancer development and progression. However, the exact roles these molecules play in breast cancer growth remain inconclusive and poorly understood \[[@B5], [@B6]\]. Therefore, identifying the differentially expressed proteins in breast cancer would be useful in understanding how the disease forms and advances. Identification of these proteins would also enable treatments that are specific to breast cancer to be formulated.

Proteomics is a large-scale study of the proteome, which is the entire compliment of expression of proteins by a living organism \[[@B7]\]. Proteomics uses tools such as two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and liquid chromatography/mass spectrometry (LC/MS) \[[@B8]\] for protein separation and analysis, respectively. This approach has been used to identify protein biomarkers in breast cancers \[[@B9]--[@B13]\] and other types of cancer \[[@B14]--[@B17]\]. Identification of protein biomarkers may have important prognostic values in the diagnosis and treatment of the disease \[[@B18], [@B19]\].

The classification and prognosis of breast cancer are based on stage and grade of the tumour \[[@B20], [@B21]\]. Both the information for grade and stage of the cancer are used to plan treatment for the patient. In this study, we aim to identify the differentially expressed aqueous soluble proteins between cancerous and normal IDC breast tissues and to relate the expression of these proteins to the grade and stage of IDC. We believe this information will contribute to the prognosis of IDC breast cancer.

2. Methods {#sec2}
==========

2.1. Breast Cancer Patients {#sec2.1}
---------------------------

Breast cancer patients were diagnosed with IDC and had undergone surgical treatment at Penang General Hospital, Penang, Malaysia. The patients were divided by stage and grade into 4 cohorts; Stages II, III and Grades II, III, respectively. Stage II, III cohorts contained 7 patients and 10 patients, respectively while Grade II and III cohorts contained 7 patients and 9 patients, respectively. Each sample set comprised cancerous and normal tissues from the same patient. The tissues were confirmed as cancerous and normal, respectively, by the hospital\'s pathologist. The information on patients\' age, stage, TNM, grade, estrogen receptor, progesterone receptor, and C-ERB-B~2~ oncoprotein status is listed in [Table 1](#tab1){ref-type="table"}.

2.2. Tissue Samples {#sec2.2}
-------------------

Human ethical clearance from the Human Ethical Clearance Committee of Universiti Sains Malaysia and the Ministry of Health, Malaysia was received prior to conducting the study. Normal and cancerous breast tissues samples from IDC patients were obtained from the Penang General Hospital, Penang, Malaysia. Informed consents from the breast cancer patients were received before the tissues were collected. The breast tissues were pathologically confirmed by the hospital\'s pathologists. Breast carcinoma tumour tissues were taken from the ductal epithelium. Frozen section of tissue morphology was taken from the cancerous tissues from the anterior and deep region to ensure tumour adequacy and only the part of the cancerous tissue that had greater than 90% malignant cells was used in this study. Tissues were stored at −80°C prior to analysis.

2.3. Protein Extraction {#sec2.3}
-----------------------

Frozen tissues were thawed at room temperature (25°C), rinsed with distilled water and homogenized on ice for 5 min. Proteins were extracted by addition of Tris buffer (TRIS) ((40 mM Tris, 1 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride (AEBSF)) to the homogenized tissue. After centrifugation (13000 rpm, 20 min, 20°C), the supernatant was collected and the protein concentration was determined in duplicates by RC-DC protein assay (Bio-Rad, USA).

2.4. Protein Preparation {#sec2.4}
------------------------

Prior to isoelectric focusing, TRIS protein extracts were first precipitated by using trichloroacetic acid (TCA)/acetone method \[[@B22]\]. Ten percent TCA in ice-cold acetone containing 20 mM dithiothreitol (DTT) was added to the TRIS extracts and incubated at −20°C for 1.5 h. After centrifugation (13000 rpm, 15 min, 4°C), the pellet was washed with ice-cold acetone containing 20 mM DTT before being centrifuged (13000 rpm, 15 min, 4°C). The supernatant was discarded and the pellet was resolubilized in thiourea lysis buffer (TLB) (8 M Urea, 2 M Thiourea, 4% (w/v) 3-\[(3-Cholamidopropyl)dimethylammonio\]-1-propanesulfonate (CHAPS), 0.4% (w/v) carrier ampholyte, 50 mM DTT, 1 mM AEBSF) and incubated for 1 h at 25°C.

2.5. 2D-Gel Electrophoresis {#sec2.5}
---------------------------

A protein extract containing 250 mg protein was passively rehydrated unto an 11 cm pH 4-7 IPG strips (Bio-Rad, USA) for 15 h at 20°C. Isoelectric focusing (IEF) was performed using the Protean IEF Cell (Bio-Rad, USA) at 20°C for 15 min at 250 V, 2.5 h at 8000 V and held at 8000 V for 30 kVh. The proteins were equilibrated by adding in equilibration buffer I (6 M Urea, 0.375 M Tris-HCl, pH 8.8, 2% SDS, 20% glycerol, 1% (w/v) DTT) to the focused IPG strip for 10 min at 25°C, followed by the addition of equilibration buffer II (6 M Urea, 0.375 M Tris-HCl, pH 8.8, 2% SDS, 20% glycerol, 2.5% (w/v) iodoacetamide) for 10 min at 25°C. The IPG strip was positioned on top of a 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) (135 × 160 × 1 mm) and electrophorised in a PROTEAN II xi Cell (Bio-Rad, USA) at a constant voltage of 200 V for 3 hours according to the method of Laemmli \[[@B23]\]. After electrophoresis, the gels were stained using Coomassie Brilliant Blue 250 (CBR-250) solution (0.1% (w/v) CBR-250, 40% (v/v) methanol, 10% (v/v) acetic acid) for 4 h. The staining background was removed by incubating the gel in a destaining solution (40% (v/v) methanol, 2% (v/v) acetic acid) twice for 2 h each.

2.6. Gel Imaging and Analysis {#sec2.6}
-----------------------------

The images of 2D-PAGE gels were captured by using Versadoc system (Bio-Rad, USA). The gel images were processed and analyzed by using PDQuest software 7.3 (Bio-Rad, USA). The software created a match set to compare the images of cancerous and normal breast tissues, which was then used to analyze quantitative and qualitative differences in protein spots between the images. Each protein spot was normalized by dividing the spot intensity with the total intensity value of all the pixels in the gel image in order to quantitate the spot and to correct slight variations in protein loading. A protein was considered as up-regulated if its expression level in cancerous tissues was increased 1.5-fold or more as compared to normal breast tissue: it was considered as down-regulated if its expression level in cancerous tissues was decreased 1.5-fold or more as compared to the normal breast tissue. The statistical significance of the protein\'s differential expression was determined by using the Wilcoxon signed-rank test available in the PDQuest software.

2.7. In Gel Digestion and Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS) Analysis {#sec2.7}
--------------------------------------------------------------------------------------------

In gel digestion was performed according to Othman et al. \[[@B24]\]. Briefly, protein spots of interest were excised from the gel. They were washed with deionized water, cut in fine pieces, hydrated and dehydrated with 100 mM ammonium bicarbonate (NH~4~HCO~3~) and acetonitrile (ACN), respectively, in order to remove the stain material. The protein was reduced *in situ* with DTT and alkylated with iodoacetamide and finally digested into peptides by treating it with trypsin. The tryptic peptides were eluted from the gel and dried under the continuous flow of nitrogen gas. Peptides were reconstituted in 30 *μ*L of 0.1% (v/v) formic acid in a solution of deionized water:acetonitrile (85 : 15) and were fractionated by RP-HPLC (C18, 150 × 0.3 mm, 5 *μ*m 300 Å) using an Agilent 1100 Series. The mobile phases A (0.1% formic acid in deionized water) and B (0.1% formic acid in ACN) are pumped at a constant flow rate of 4 *μ*L/min. The peptides were eluted by a linear gradient of 5% B to 95% B in 70 min and held constant at 95% B for 5 min. The HPLC was interfaced to an ESI-ion trap mass analyzer (Agilent). Two types of scan were performed: full scan MS and full scan MS/MS, where the two most intense ions in an MS scan that exceeded the set threshold of 5000 counts will be isolated for MS/MS scan to produce a series of product ions spectrum for protein identification. The instrumental parameters used were Nebulizer pressure at 20.0 psi, auxiliary dry gas flow of 6.0 L/min, auxiliary dry gas temperature at 300°C, capillary voltage at 3.5 kV, exit capillary voltage 84.5 V, skimmer 1 voltage at 17.2 V, skimmer 2 voltage at 6.0 V. MS scan region from 200--1800 m/z with a scan time 1 s and a interscan time of 0.1 s. The MS/MS scan parameters were Default collision energy (voltage) of 1.15 V, charge state of 2, minimum threshold of 5000 counts, and isolation width of 2 m/z. Protein identification was done by submitting the MS/MS data to a MASCOT database search engine at <http://www.matrixscience.com/>. The search parameters used were *Homo sapiens* for taxonomy, carboxymethyl for fixed modifications, peptide tolerance of ±2 Da, MS/MS tolerance of ±0.8 Da, and average experimental mass value.

2.8. Western Blotting {#sec2.8}
---------------------

Western blotting was carried out using a semidry method according to Lauriere \[[@B25]\]. Protein extracts were separated by one-dimensional SDS-PAGE according to Laemmli \[[@B23]\]. The gel was incubated in a cold transfer buffer (25 mM Tris, 192 mM Glycine and 1.3 mM SDS, pH 8.3) for 30 min. The proteins were transferred from the gel to a nitrocellulose membrane (Bio-Rad, USA) in a TE 70 Semiphor semidry transfer unit (Hoefer Scientific, Germany) at 134 mA for 1.5 h. The membrane was incubated with blocking buffer (3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline (PBS)) for 2 h at 25°C. After washing with PBS, the membrane was incubated in 20 mL of mouse antiannexin V antibody (Abnova, Taiwan) with a 1 : 2000 dilution in antibody diluent buffer (0.1% (w/v) BSA, 0.1% Tween 20, 0.02% sodium azide in PBS) overnight at 25°C. After PBS washing, the membrane was incubated in 50 mL of horseradish peroxidase (HRP) conjugated anti-mouse secondary antibody (Bio-Rad, USA) at 1 : 3000 dilution for 2 h at 25°C. After being washed with PBS, 20 mL of 4-Chloro naphthol (4CN), substrate solution (Bio-Rad, USA) was added to the membrane until the band is visualized.

3. Results {#sec3}
==========

In this study, similar amount of protein and identical separation and staining conditions were applied to all the samples. Although the pattern of the 2D images for cancerous and normal breast tissues was relatively similar, the intensities of the spots varied between the tissues types. [Figure 1](#fig1){ref-type="fig"} shows examples of 2D images of cancerous and normal tissues obtained from the same patient. The difference in spots intensities indicates the differentially expressed proteins between the cancerous and normal tissues, these spots were excised and subjected to mass spectrometry analysis for protein identification. These spots are shown in [Figure 2](#fig2){ref-type="fig"}. A total of 24 differentially expressed protein spots were subjected to further analysis and the protein identities were listed in [Table 2](#tab2){ref-type="table"}. The grand average of hydropathy (GRAVY) scores indicate the polarity of the proteins, the more negative the score represents the higher hydrophilicity of the protein. [Figure 3](#fig3){ref-type="fig"} shows the MS and MS/MS spectra of one of the proteins. After being subjected to MASCOT protein database search, the peptide was found to belong to annexin V; the identity of the protein was further confirmed by western blotting experiment shown in [Figure 4](#fig4){ref-type="fig"}. Out of the 24 proteins, four proteins were up-regulated while one protein was down-regulated in \>75% of patients tested. The up-regulated proteins was SEC13-like 1 (isoform b), calreticulin, 14-3-3 protein zeta and 14-3-3 protein eta. The down-regulated protein was fibrinogen beta chain precursor. The Wilcoxon signed-rank test was used to determine the statistical significance of the changes in protein expression levels between the two tissues types. The differential expression of these proteins were statistically significant with a 95% confidence level (*P* \< .05). The expression levels of the rest of the proteins identified were inconsistent between patients, where their expression levels range from 6% to 67% variation. We did not detect any unique protein from cancerous or normal tissues. [Figure 5](#fig5){ref-type="fig"} shows the expression levels of the 24 proteins in all the patients; the expression levels were categorized as upregulation, equal expression, downregulation or nonexpression in the patients tested.

Nine up-regulated proteins and one down-regulated proteins were detected at a significant level (*P* \< .05) in \>70% of the Stage II patients (*n* = 7). The proteins that up-regulated were superoxide dismutase, peroxiredoxin-2, serum albumin precursor, class IV beta tubulin, SEC13-like 1 (isoform b), calreticulin, unidentified protein, 14-3-3 protein zeta and 14-3-3 protein eta while fibrinogen beta chain precursor was significantly down-regulated. Haptoglobin precursor which was down-regulated in \>70% stage II patients was not statistically significant. In contrary, Hypothetical protein (protein spot 16) was down-regulated in \<70% of Stage II patients, but the change in its expression level was statistically significant. [Figure 6](#fig6){ref-type="fig"} shows the percentage of upregulation, equal expression, downregulation and nonexpression of the proteins in Stage II patients.

Four proteins were up-regulated and one protein was down-regulated significantly (*P* \> .05) in \>70% of the Stage III patients (*n* = 10) tested. These up-regulated proteins were SEC13-like 1 (isoform b), calreticulin, 14-3-3 protein zeta and 14-3-3 protein eta, while the down-regulated protein was fibrinogen beta chain precursor. Glutathione transferase was up-regulated in \>70% of Stage III patients but the change in its expression level was not statistically significant. On the other hand, superoxide dismutase, serum albumin precursor, class IV beta tubulin, and F-actin capping protein were up-regulated in \<70% of Stage III patients, however, their upregulations were statistically significantly in Stage III patients. Haptoglobin precursor was significantly down-regulated in \<70% of Stage III patients. [Figure 7](#fig7){ref-type="fig"} shows the percentage of upregulation, equal expression, downregulation and nonexpression of the proteins for Stage III patients.

Five proteins were significantly (*P* \< .05) up-regulated in \>70% of the Grade II patients (*n* = 7). These proteins were superoxide dismutase, class IV beta tubulin, SEC-like 1 (isoform b), calreticulin and F-actin capping protein. Glutathione transferase, 14-3-3 protein zeta, and 14-3-3 protein eta were up-regulated in \>70% of Grade II patients but their upregulation was not statistically significant. On contrary, peroxiredoxin-2 was significantly up-regulated in \<70% of Grade II patients. [Figure 8](#fig8){ref-type="fig"} shows the percentage of upregulation, equal expression, downregulation and nonexpression of the proteins in Grade II patients.

Seven up-regulated proteins and one down-regulated proteins were significantly expressed in \>70% of Grade III patients (*n* = 9). The up-regulated proteins were peroxiredoxin-2, SEC-like 1 (isoform b), calreticulin, unidentified protein, hypothetical protein, 14-3-3 protein zeta and 14-3-3 protein eta while the down-regulated protein was fibrinogen beta chain precursor. Additionally, superoxide dismutase, serum albumin precursor and class IV beta tubulin were significantly up-regulated while haptoglobin precursor was significantly down-regulated in \<70% of Grade III patients. [Figure 9](#fig9){ref-type="fig"} shows the percentage of upregulation, equal expression, downregulation and nonexpression of the proteins in Grade III patients.

There were 12 proteins that were up-regulated significantly in at least one of the stage and grade. [Figure 10](#fig10){ref-type="fig"} shows the upregulation of these proteins in stage II, stage III, grade II, and grade III patients. Superoxide dismutase was up-regulated at 71% in stage II and grade II patients and at 60% in stage III and grade III patients. Peroxiredoxin-2 was up-regulated at 86% in stage II patients and at 50%, 57% and 50% in stage III, grade II and grade III patients, respectively. Serum albumin precursor was up-regulated at 86% in stage II patients and at 50%, 57% and 67% in stage III, grade II and grade III patients, respectively. Glutathione transferase was up-regulated at 70% and 71% in stage III and grade II patients, respectively. Its upregulation in stage II and grade III patients were 57% and 67%, respectively. Class IV beta-tubulin was up-regulated at 71% in both stage II and grade II patients and at 50% and 67% in stage III and grade III patients, respectively. SEC13-like 1 was up-regulated at 71%, 90%, 86% and 78% in stage II, III, grade II and III patients, respectively. Calreticulin was up-regulated at 86%, 100%, 100% and 89% in stage II, III, grade II and III patients, respectively. The unidentified protein (protein spot 16) was up-regulated at 86% and 78% of stage II and grade III patients, respectively and at 50% and 57% in stage III and grade II patients, respectively. Hypothetical protein was up-regulated at 78% in grade III patients and at 57%, 60% and 43% in stage II, III and grade II patients, respectively. 14-3-3 protein zeta was up-regulated in all stage and grade groups at 100%, 80%, 71% and 100% in stage II, III, grade II and III patients, respectively. 14-3-3 protein eta was up-regulated in 85%, 80% and 100% of stage II, III and grade III patients, respectively. However, its upregulation in grade II patients was only 57%. F-actin capping protein was up-regulated at 85% in grade II patients and at 57%, 60% and 56% in stage II, III and grade III patients, respectively.

4. Discussion {#sec4}
=============

Tissues heterogeneity is the main problem encountered when conducting proteomic analysis on tissue specimens. In this study, only the part of cancerous tissues with \>90% malignancy was used to ensure tumour adequacy. We used the normal tissue adjacent to the tumour tissue for comparison purpose, we found that this is crucial due to tissue heterogeneity between patients, although there was a consistent protein profiles obtained from the patients, the profiles were not identical. This can be explained as proteins are expression components of cells, and therefore they will be expressed differently under different environment which caused as variations between tissues from different patients; therefore, the best comparison for protein expression would be between the cancerous and normal tissues from the same patients. Despite this, the drawback of using such normal tissues as the control is that these tissues may possess some molecular and epigenetic abnormalities. We overcome this problem by only collecting the normal tissues that were confirmed normal by pathologist; a minute contamination that derived from tissue abnormalities would be excluded as the minute proteins derived from the abnormal tissues would not be detected under Commassie blue staining. In addition, we focused only on the proteins that showed consistent expression in the patients in order to minimize false identification of protein that resulted from tissue heterogeneity between patients or sample handling (Seng et al. \[[@B45]\]). Furthermore, normalization of the gel intensity was carried out prior to the determination of the target protein spots intensities, where the intensity of each protein spot was calculated as the percentage to the total intensity of all the spots on the same image. This approach was taken to reduce the variation in protein spot intensity that may be caused by variability in sample loading. The main limitation of this study is the number of tissues used, nevertheless, potential biomarkers with consistent and significant upregulation in patients were identified that worth further investigation with a greater number of tissues.

Since proteins are the functional components of cells that regulate cell\'s activity, it would be interesting to relate the expression of the differentially expressed proteins with the various stages and grades of tumour. We have identified a few proteins that can be strongly and significantly related with certain stages and grades of IDC. 14-3-3 protein zeta was found up-regulated significantly (*P* \< .05) in all (100%) the patients with grade III cancer and also in all the patients with stage II cancer while 14-3-3 protein eta was detected up-regulated significantly in all (100%) the grade III patients tested. Calreticulin was found to be a good biomarker for all the grades and stages tested in this study, where its expression levels were 100% in grade II patients and also stage III patients, respectively, and as for grade III patients and stage II patients, its expression levels were greater than 80% in both the two cohorts. Other proteins with \>80% expression levels in grade II patients were F-actin capping protein and SEC13-like 1 protein. In stage III patients, 14-3-3 protein eta, 14-3-3 protein zeta and SEC13-like 1 were expressed at ≥80%. 14-3-3 protein eta, an unidentified protein (60 kDa), calreticulin, serum albumin precursor and peroxiredoxin-2 were expressed at \>80% in stage II patients. In general, we have identified four proteins that can be strongly and significantly related to at least one of the stages or grades tested in this study, these proteins were SEC13-like 1, calreticulin, 14-3-3 protein zeta and 14-3-3 protein eta.

There was an interesting trend of expressions shown by these four proteins, whereby both the 14-3-3 protein eta and zeta were shown to be strongly related with grade III patients and stage II patients indicating that the proteins may be associated with the aggressiveness of the tumour before the tumour spread. On the other hand, calreticulin and SEC13-like 1 were related more strongly with grade II patients and stage III patients indicating that as the tumour has spread to lymph nodes, the expression of these proteins increases.

Besides stage and grade, the expression levels of a few receptors such as progesterone, estrogen and C-ERB-B~2~ and the combinations of the three receptors as triple positive and triple negative grading were also used in the prediction of the prognosis of the disease. In this study, we found that within the stages and grades tested, the expressions of the four proteins were not correlated with the expressions of these receptors (see supplementary material available online at doi: 10.1155/2010/516469).

Calreticulin is a 48 kDa multifunctional calcium ion-binding protein that regulates cellular activities in the endoplasmic reticulum (ER) \[[@B26]\]. It binds to misfolded proteins to prevent them from being transported to the Golgi apparatus. Calreticulin has been reported to be highly expressed in human breast ductal carcinoma cells compared to normal breast cells \[[@B27]--[@B29]\].

14-3-3 eta protein (YWAH) and 14-3-3 zeta protein (YWAZ) are subunits of the 14-3-3 isoform proteins (14-3-3). These proteins bind to proteins which are involved in the signaling pathway, including kinases and transmembrane receptors. 14-3-3 interact with signaling proteins to regulate a wide variety of cellular events \[[@B30]--[@B34]\]. 14-3-3 regulate cancer-related processes, where they inhibit apoptosis, act as cell cycle checkpoints \[[@B35], [@B36]\] and control oncogene products that are overexpressed in cancer cells \[[@B37]\]. 14-3-3 were up-regulated in breast ductal carcinoma tumour cells \[[@B38]\].

Protein SEC13 homolog (SEC13) belongs to the SEC13 family of WD-repeat proteins. SEC13 is required in the production of vesicles from the ER to the Golgi apparatus for the transport of proteins \[[@B39]\]. Its involvement in cancer has not yet been reported.

Serum albumin precursor is used for the synthesis of Human serum albumin (HSA), an endogenous plasma protein and it is the main component of the blood transport system. HSA transports and binds with water, hormones, fatty acids, metal ions and drugs. It also maintains blood osmotic pressure and pH besides acting as antioxidant in removing reactive oxygen species in the blood plasma \[[@B40]\]. Nevertheless, HSA levels and characteristics in cancer cells might have been modified from normal HSA \[[@B41]\]. The albumin portion of HSA exerts a growth inhibition in breast cancer cells that may affect cell proliferation by modulating the activities of growth factors \[[@B42]\]. HSA was a potent stimulator of estrone sulphatase activity and therefore contributes directly to the high estrogen concentrations found in breast cancer \[[@B43]\]. In addition to breast cancer, HSA was found accumulated in tumours in ovarian cancer \[[@B44]\].

5. Conclusion {#sec5}
=============

The major limitation of this study is its sample size, nevertheless, the proteins identified were found consistently up-regulated in the patients tested and their upregulations were significant statistically (*P* \< .05) indicating their possible roles in the development of the disease. The expressions levels of SEC13-like 1 (isoform b), calreticulin, 14-3-3 protein zeta, and 14-3-3 protein eta were found significantly related to certain stages or grades of the IDC breast tumour tissues. In view of their consistent (100%) upregulated expression in specific stage or grade of IDC breast tumour, their potential use as biomarkers for diagnosis, prognosis, or treatment of IDC breast cancer is undeniable.

Supplementary Material {#supplementary-material-sec}
======================

###### 

In this study, we have evaluated the expressions of the identified biomarkers in relation to the hormone receptors, we find that for both grade-related and stage-related biomarkers, their expressions were not related to the expressions of the hormone receptors, namely estrogen receptor, progesterone receptor, C-ERB-B2 oncoprotein status and triple negative status.

###### 

Click here for additional data file.
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![(a) 2D gel image of TRIS extract from (i) normal and (ii) cancer breast tissues of same patient. (b) Protein spot intensity of (i) calreticulin and (ii) 14-3-3 protein zeta from normal and cancerous tissue of same patient.](JBB2010-516469.001){#fig1}

![Protein spots selected for in-gel digestion.](JBB2010-516469.002){#fig2}

![Identification of protein. (a) Full scan MS spectrum of peptide eluted out at 32.4 minutes. (b) MS/MS spectrum of 610.4 product ions. (c) Amino acid sequence of peptide eluted out 32.4 minutes.](JBB2010-516469.003){#fig3}

![Immunoblot of annexin V. Lane M: protein molecular weight markers (in kDa). Lane 1: normal TRIS extract from first patient. Lane 2: cancer TRIS extract from first patient. Lane 3: normal TRIS extract from second patient. Lane 4: cancer TRIS extract from second patient.](JBB2010-516469.004){#fig4}

![Distribution of proteins in TRIS extracts of all patients. The expression of proteins was defined as upregulation, downregulation, equal expression, and nonexpression in each patient.](JBB2010-516469.005){#fig5}

![Distribution of proteins in Stage II patients.](JBB2010-516469.006){#fig6}

![Distribution of proteins in Stage III patients.](JBB2010-516469.007){#fig7}

![Distribution of proteins in Grade II patients.](JBB2010-516469.008){#fig8}

![Distribution of proteins in Grade III patients.](JBB2010-516469.009){#fig9}

![Comparison of up-regulated proteins in Stage II, Stage III, Grade II and Grade III patients.](JBB2010-516469.010){#fig10}

###### 

Patient information.

  -----------------------------------------------------------------------------------------------
  Patient no.   Age   Stage   TNM               Grade   Estrogen\   Progesterone\   C-ERB-B~2~\
                                                        receptor    receptor        oncoprotein
  ------------- ----- ------- ----------------- ------- ----------- --------------- -------------
  1             54    3       T~2~N~1~M~*x*~    1       Positive    Positive        Negative

  2             67    2       T~2~N~0~M~*x*~    3       Negative    Negative        Negative

  3             60    3       T~2~N~1~M~*x*~    2       Positive    Positive        Positive

  4             74    3       T~2~N~1~M~*x*~    2       Positive    Positive        Negative

  5             67    3       T~3~N~1~M~*x*~    2       Negative    Negative        Positive

  6             78    3       T~4~N~1~M~*x*~    3       Positive    Positive        Negative

  7             64    3       T~3~N~1~M~*x*~    3       Negative    Negative        Positive

  8             63    2       T~2~N~0~M~*x*~    3       Positive    Negative        Positive

  9             65    2       T~2~N~1~M~*x*~    3       Negative    Negative        Negative

  10            59    2       T~2~N~1~M~*x*~    3       Negative    Negative        Negative

  11            55    4       T~4~N~*x*~M~1~    3       Positive    Negative        Negative

  12            72    2       T~2~N~0~M~*x*~    2       Positive    Negative        Negative

  13            80    3       T~3~N~1~M~*x*~    2       Positive    Positive        Negative

  14            60    2       T~2~N~1~M~*x*~    3       Negative    Negative        Negative

  15            62    2       T~2~N~1~M~*x*~    3       Negative    Negative        Positive

  16            ---   3       T~4B~N~1~M~*x*~   1       Positive    Positive        Positive

  17            54    3       T~2~N~2~M~*x*~    2       Negative    Negative        Negative

  18            64    3       T~3~N~0~M~*x*~    2       Positive    Positive        Negative
  -----------------------------------------------------------------------------------------------

###### 

Identity and properties of twenty-four differentially expressed proteins.

  Protein spot no.   SwissProt Accession Number   Protein name                                  Molecular class           Molecular weight (Da)   Isoelectric point (pI)   GRAVY score   MOWSE score   Sequence coverage (%)
  ------------------ ---------------------------- --------------------------------------------- ------------------------- ----------------------- ------------------------ ------------- ------------- -----------------------
  1                  P02768                       Serum albumin precursor                       Transport/cargo           71397                   5.92                     −0.354        96            14
  2                  P00441                       Superoxide dismutase                          Oxidoreductase            16168                   5.70                     −0.344        52            9
  3                  P32119                       Peroxiredoxin-2                               Oxidoreductase            21935                   5.67                     −0.199        260           26
  4                  P00739                       Haptoglobin-related precursor                 Transport/cargo           39529                   6.42                     −0.308        43            3
  5                  P02766                       Transthyretin precursor                       Transport/cargo           16003                   5.52                     −0.029        75            22
  6                  P15090                       Fatty acid binding protein                    Carrier protein           14704                   6.81                     −0.249        223           24
  7                  P00738                       Haptoglobin precursor, allele 2 (validated)   Transport/cargo           45901                   6.13                     −0.421        56            6
  8                  P02768                       Serum albumin precursor (validated)           Transport/cargo           69366                   5.92                     −0.354        46            4
  9                  P00739                       Haptoglobin- related protein precursor        Transport/cargo           39529                   6.42                     −0.308        55            3
  10                 P09211                       Glutathione transferase                       Transferase               23464                   5.42                     −0.121        277           53
  11                 P68371                       Class IV beta tubulin                         Structural protein        50217                   4.82                     −0.362        52            13
  12                 P55735                       SEC13-like 1, isoform b                       Transport/cargo           36062                   5.22                     −0.372        115           37
  13                 P02675                       Fibrinogen beta chain precursor               Coagulation factor        56624                   8.54                     −0.758        87            28
  14                 P02675                       Fibrinogen beta chain precursor               Coagulation factor        56624                   8.54                     −0.758        134           31
  15                 P27797                       Calreticulin                                  Calcium binding protein   47092                   4.30                     −1.104        107           29
  16                 Not available                Unidentified protein                          N/A                       N/A\*                   N/A                      N/A           N/A           N/A
  17                 Q63610                       Hypothetical protein                          Hypothetical protein      27407                   4.71                     −0.992        59            27
  18                 P63104                       14-3-3 protein zeta (kinase regulator)        Adaptor molecule          27745                   4.73                     −0.621        193           47
  19                 Q04917                       14-3-3 protein eta                            Adaptor molecule          28244                   4.76                     −0.618        71            23
  20                 P52907                       F-actin capping protein                       Cytoskeletal protein      32965                   5.45                     −0.668        53            26
  21                 P02766                       Transthyretin precursor                       Transport/cargo           16003                   5.52                     −0.029        85            22
  22                 P68133                       Actin alpha                                   Cytoskeletal protein      38172                   5.39                     −0.161        64            17
  23                 P07195                       L-lactate dehydrogenase                       Dehydrogenase             36928                   5.71                     0.056         222           34
  24                 P21695                       Glycerol-3-phosphate dehydrogenase            Dehydrogenase             38206                   5.81                     0.106         312           51

[^1]: Academic Editor: Anne Hamburger
